Prostate cancer vaccine - Jenner Biotherapies

Drug Profile

Prostate cancer vaccine - Jenner Biotherapies

Alternative Names: JBT 1001; OncoVax-Pr

Latest Information Update: 24 Aug 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jenner Biotherapies (CEASED)
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 24 Aug 2005 No development reported - Phase-II for Prostate cancer in USA (Injection)
  • 22 Aug 2000 A interim analysis of a phase II trial has been added to the Cancer therapeutic trials section
  • 04 Mar 1999 Jenner Biotherapies has been awarded a US patent covering the use of prostate-specific antigen in prostate cancer vaccines
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top